BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 23940247)

  • 1. First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia.
    Favier R; Feriel J; Favier M; Denoyelle F; Martignetti JA
    Pediatrics; 2013 Sep; 132(3):e793-5. PubMed ID: 23940247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations.
    Pecci A; Gresele P; Klersy C; Savoia A; Noris P; Fierro T; Bozzi V; Mezzasoma AM; Melazzini F; Balduini CL
    Blood; 2010 Dec; 116(26):5832-7. PubMed ID: 20844233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eltrombopag to allow chemotherapy in a patient with MYH9-related inherited thrombocytopenia and pancreatic cancer.
    Paciullo F; Bury L; Gresele P
    Int J Hematol; 2020 Nov; 112(5):725-727. PubMed ID: 32557126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eltrombopag to Treat Thrombocytopenia During Last Month of Pregnancy in a Woman With MYH9-Related Disease: A Case Report.
    Favier R; De Carne C; Elefant E; Lapusneanu R; Gkalea V; Rigouzzo A
    A A Pract; 2018 Jan; 10(1):10-12. PubMed ID: 28795988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure.
    Arif AR; Zhao M; Chen W; Xue M; Luo S; Wang Y
    Platelets; 2022 Nov; 33(8):1307-1311. PubMed ID: 35791514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease.
    Verver EJ; Topsakal V; Kunst HP; Huygen PL; Heller PG; Pujol-Moix N; Savoia A; Benazzo M; Fierro T; Grolman W; Gresele P; Pecci A
    Ear Hear; 2016; 37(1):112-20. PubMed ID: 26226608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag in thrombocytopenia.
    Lawson A
    N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18322290
    [No Abstract]   [Full Text] [Related]  

  • 8. Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation.
    Pecci A; Barozzi S; d'Amico S; Balduini CL
    Thromb Haemost; 2012 Jun; 107(6):1188-9. PubMed ID: 22398565
    [No Abstract]   [Full Text] [Related]  

  • 9. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag in preparation for surgery in patients with severe MYH9-related thrombocytopenia.
    Zaninetti C; Barozzi S; Bozzi V; Gresele P; Balduini CL; Pecci A
    Am J Hematol; 2019 Aug; 94(8):E199-E201. PubMed ID: 31034630
    [No Abstract]   [Full Text] [Related]  

  • 11. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
    Di Buduo CA; Laurent PA; Zaninetti C; Lordier L; Soprano PM; Ntai A; Barozzi S; La Spada A; Biunno I; Raslova H; Bussel JB; Kaplan DL; Balduini CL; Pecci A; Balduini A
    Elife; 2021 Jun; 10():. PubMed ID: 34059198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative use of platelets in a 6-year-old with acute appendicitis and a myosin heavy chain 9-related disorder: a case report and review of literature.
    Eichel Y; Tormos LM; Squires JE
    Transfusion; 2016 Feb; 56(2):349-53. PubMed ID: 26446054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
    Afdhal NH; Giannini EG; Tayyab G; Mohsin A; Lee JW; Andriulli A; Jeffers L; McHutchison J; Chen PJ; Han KH; Campbell F; Hyde D; Brainsky A; Theodore D;
    N Engl J Med; 2012 Aug; 367(8):716-24. PubMed ID: 22913681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecule of the month. Eltrombopag.
    Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592
    [No Abstract]   [Full Text] [Related]  

  • 15. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
    McHutchison JG; Dusheiko G; Shiffman ML; Rodriguez-Torres M; Sigal S; Bourliere M; Berg T; Gordon SC; Campbell FM; Theodore D; Blackman N; Jenkins J; Afdhal NH;
    N Engl J Med; 2007 Nov; 357(22):2227-36. PubMed ID: 18046027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag.
    Scheinberg P; Singulane CC; Barbosa LS; Scheinberg M
    Clin Rheumatol; 2014 Sep; 33(9):1347-9. PubMed ID: 24740463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia.
    Gerrits AJ; Leven EA; Frelinger AL; Brigstocke SL; Berny-Lang MA; Mitchell WB; Revel-Vilk S; Tamary H; Carmichael SL; Barnard MR; Michelson AD; Bussel JB
    Blood; 2015 Sep; 126(11):1367-78. PubMed ID: 26224646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease.
    Pecci A; Panza E; Pujol-Moix N; Klersy C; Di Bari F; Bozzi V; Gresele P; Lethagen S; Fabris F; Dufour C; Granata A; Doubek M; Pecoraro C; Koivisto PA; Heller PG; Iolascon A; Alvisi P; Schwabe D; De Candia E; Rocca B; Russo U; Ramenghi U; Noris P; Seri M; Balduini CL; Savoia A
    Hum Mutat; 2008 Mar; 29(3):409-17. PubMed ID: 18059020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
    Cheng G; Saleh MN; Marcher C; Vasey S; Mayer B; Aivado M; Arning M; Stone NL; Bussel JB
    Lancet; 2011 Jan; 377(9763):393-402. PubMed ID: 20739054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful use of eltrombopag for surgical preparation in a patient with ANKRD26-related thrombocytopenia.
    Fiore M; Saut N; Alessi MC; Viallard JF
    Platelets; 2016 Dec; 27(8):828-829. PubMed ID: 27276516
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.